American Premium Water Corp. (HIPH)

The QualityStocks Daily Newsletter would like to spotlight American Premium Water Corp. (HIPH).

American Premium Water Corporation (OTC Pink: HIPH) (the “Company”) announces that SeeThruEquity has revised upwards its initial price target for the Company from $0.15 to a revised target price of $0.30, with the report adding, "intriguing speculative growth company, targeting large consumer opportunities… with the launch of LALPINA Hydro CBD and its subsequent ecommerce distribution announcements with SingleSeed.com and DIGSHydro.com, subsidiaries of SinglePoint, Inc, as well as strategic deals expanding the company’s presence in the luxury consumer markets.”

American Premium Water Corp. (HIPH), headquartered in Playa Vista, California, is a diversified holding company, manufacturer, distributor and marketer of branded consumer products. HIPH, the acronym for “Hi-Power of Hydro,” maintains a portfolio of subsidiaries catering to the health-conscious consumer and luxury fashion brand connoisseur. The company’s two main pillars focus on the development of health and beauty biotech, dedicated to unlocking the power of hydrogen and nanotechnologies. Paired with cannabidiol or “CBD” in a unique beverage, the technology is proving to be a significant health and wellness option for astute consumers.

Among the company’s holdings are:

• LALPINA Hydro beverages mix hydrogen with nanotechnology into consumer beverages that combine the best of health, nutrition and fitness to deliver short and long-term therapeutic health benefits. LALPINA Hydro utilizes atomic molecular hydrogen, or diatomic hydrogen, which converts antioxidants in the body to H2O to further enhance hydration, which helps increase endurance, reduce lactic acid and melt away fatigue. Over 500 peer-reviewed articles demonstrate hydrogen to have therapeutic potential in essentially every organ of the human body and in 150 different human disease models.
• LALPINA Hydro CBD is a technically superior CBD-infused beverage. Using hydro and nanotechnology, LALPINA Hydro CBD encapsulates water molecules with cannabidiol molecules, making them infinitely more bioavailable and accelerating delivery to the body’s cells and tissues. Each bottle of LALPINA Hydro CBD contains 3 million nanograms of CBD free from the psychoactive compound THC (tetrahydrocannabinol). HIPH is the first to introduce a hydro-nano CBD-infused beverage on the market, which is a more effective delivery mechanism for administering CBD into the blood stream than traditional beverages or oils, with up to a 90 percent higher absorption rates.

The company recently signed a distribution agreement for its subsidiary, LALPINA Hydro CBD, to sell its beverages to two SinglePoint, Inc. (OTCQB: SING) e-commerce channels: SingleSeed.com and DIGSHydro.com. SING is a technology and investment company with a portfolio that includes mobile payments, blockchain solutions and ancillary cannabis services. HIPH will drop ship its product to the customers.

HIPH CEO Ryan Fishoff said the e-commerce arrangements “could bring in excess of a million of revenue over the life of the agreement.” The agreement serves as a pillar of the company’s e-commerce distribution strategy, driving awareness and impressions for the LALPINA brand.

In addition, HIPH seeks to market emerging fashion brands and leverage its relationship with classic retail partners while incorporating disruptive blockchain technologies to expand its retail footprint with the following:

• Gents, a producer of luxury hats and other fine accessories and apparel, was acquired in September 2017. Gents is distributed across many luxury retail outlets including Saks Fifth Avenue, Bloomingdales, Nordstrom, and other high-end channels. The company added the Worthy streetwear brand to its portfolio in June 2018.
• HIPH also acquired the license to operate the FashionCoinX exchange, a blockchain exchange focused on creating utility tokens for the fashion industry, and created THRD Coin, a multi-branded utility rewards token that is also the first token to be traded on the exchange. The company is leveraging its retail footprint and expertise in the fashion and apparel space with the burgeoning blockchain sector.

American Premium Water Corp. (HIPH), closed the day's trading session at $0.0709, off by 1.53%, on 32,265,547 volume with 1,479 trades. The average volume for the last 3 months is 12,926,941 and the stock's 52-week low/high is $0.0035/$0.132.

Recent News

• SeeThruEquity Announces Increased Target for American Premium Water Corporation (OTC:HIPH)
• CannabisNewsBreaks – American Premium Water Corp. (HIPH) Brings First Hydro-nano CBD Beverage to Market
• American Premium Water Corp.’s (HIPH) Agreement with SinglePoint, Inc. (SING) Seen as Pillar of HIPH’s E-Commerce Distribution Strategy

Sharing Services, Inc. (SHRV)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services, Inc. (SHRV).

Sharing Services (OTCQB: SHRV), a diversified holding company, has remained committed to achieving both corporate and individual entrepreneurial success as the company continues to see growth. To view the full article, visit: http://nnw.fm/BOi4J.

Sharing Services, Inc. (SHRV), headquartered in Plano, Texas, is a diversified holdings company focused on reshaping how entrepreneurs succeed today. Sharing Services Inc. owns, operates or controls an interest in a variety of companies specializing in the direct selling industry that either sell products to the consumer directly through independent representatives or offer services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits. SHRV has created the “Blue Ocean Strategy,” which melds three keys together to implement the company’s vision. These keys include elevating home-based entrepreneurs, known as “Elepreneurs,” utilizing the direct selling channel to generate 100 percent organic growth.

Sharing Services Inc. subsidiaries include:

• A growing international network of home-based entrepreneurs, called “Elepreneurs”
• Growing selection of health and wellness products dedicated to elevating the well-being of all people
• Insurance from auto, home and life to health benefit discounts and health insurance that help families elevate their options
• Wholesale travel and payment programs with travel concierges that empower more families to go on vacation
• Live seminars and training events – from Vacationars™ to EduTainment – that elevate the skills and knowledge of entrepreneurs around the world
• Unique compensation and reward programs crafted to help entrepreneurs elevate their health, wealth and happiness

Sharing Services recently expanded its corporate footprint by moving to a 10,000 square foot facility in Plano, Texas, that offers room to expand as the company grows and its subsidiaries flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

“The opportunity to expand to the rest of this new building over the course of the next six to 12 months ensures we won’t have to move again anytime soon,” Sharing Services Inc. Chairman Robert Oblon said. “We are on track for very significant growth here in the U.S., as well as upcoming international expansion, so this move is in preparation for what’s in front of us.”

The company recently signed a joint venture agreement with Health Wealth & Happiness Limited (“HWH”) to expand its “Elepreneurs” brand and market its products throughout Asia. The newly formed company will be named “Elepreneurs Asia Limited” and will have marketing and sales rights to China, Hong Kong, Macau, South Korea, Japan, Taiwan, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam and Papua, New Guinea. A soft launch of the Elepreneur program is scheduled sometime later in 2018 with HWH CEP Fai Chan and his team leading the effort. Formed in Hong Kong, Health Wealth & Happiness Limited is dedicated to working with visionary partners like Sharing Services Inc. to deliver the best products and services to improve the well-being of consumers.

Nearly 1,000 people attended Sharing Services, Inc.’s first “Elepreneur Happiness Convention,” held March 2-3, 2018, in Dallas, Texas. Attendees arrived from several countries including the U.S., Canada, Mexico, Singapore and Hong Kong. Keynote speakers included several internationally known motivational leaders – Shawn Achor, Sandra Yancey, John Fleming and Les Brown – who provided exceptional material and inspirational discussion points.

“The enthusiasm of our attendees and the early success that we are experiencing is incredible considering our growth has been 100 percent organic, with almost no marketing from the company,” Oblon said. “I’m speechless by the dedication of our Elepreneur leaders and their entire teams, as they share our incredible line of products that have helped so many people.”

Sharing Services and its management team plan to travel the U.S. to hold several mini conferences to expand on the messages presented at its Happiness Convention that focus on helping people become “healthier, happier and wealthier.” Details of the company’s aggressive global expansion initiatives are soon to be announced, Oblon said.

The law firm of Gardere Wynne Sewell LLP has been retained as outside corporate counsel for all general business matters. The Dallas-based law firm will represent Sharing Services, Inc., and its subsidiaries as the company utilizes the direct selling channel for a significant component of its overall growth strategy.

John “JT” Thatchwas appointed president and chief executive officer of Sharing Services, Inc., at a March 1, 2018, annual shareholder meeting. Thatch has successfully started, owned and operated several sized businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist Sharing Services Inc. as the company aims to expand and increase revenues.

Sharing Services, Inc. (SHRV), closed the day's trading session at $0.23255, up 16.27%, on 11,460 volume with 7 trades. The average volume for the last 3 months is 15,545 and the stock's 52-week low/high is $0.125/$0.695.

Recent News

• NetworkNewsBreaks – Sharing Services, Inc. (SHRV) Concentrates on Corporate and Individual Entrepreneurial Success
• Sharing Services Names Network Marketing Industry Icon Larry Thompson as New Business Strategist
• NetworkNewsBreaks – Sharing Services, Inc. (SHRV) Constantly Breaking Records in 2018

Golden Developing Solutions, Inc. (DVLP)

The QualityStocks Daily Newsletter would like to spotlight Golden Developing Solutions, Inc. (DVLP).

Golden Developing Solutions, Inc. (OTCMKTS:DVLP) (“DVLP” or the “Company”), an emerging leader in the Cannabis and CBD marketplace, is excited to announce that it has begun formal negotiations with the intention of acquiring a premier CBD Oil company (the “Acquisition Target”) to be identified in an ensuing press release.

Golden Developing Solutions, Inc. (DVLP), an emerging leader in ancillary software and the cannabidiol (CBD) products marketplace, provides business services and/or products supporting the cannabis industry including an online retail business for CBD, hemp oil and health/wellness related products.

Global acceptance of cannabis and related CBD products continues to increase as North America advances toward favorable legislation. Canada is set to legalize recreational cannabis in October 2018, and the United States has 30 states and the District of Columbia allowing either recreational or medical cannabis, or both. Voters in four additional U.S. states will consider marijuana initiatives on the November 2018 ballot. The global legal cannabis market is projected to reach USD$146 billion by the end of 2025, with a greater acceptance of medical cannabis products as a driving factor, according to Grand View Research.

DVLP is taking advantage of consumer demand for CBD products through its wholly owned Pura Vida Vitamins, LLC subsidiary, which recently launched a direct-to-consumer website (www.PuraVidaVitamins.com) and commenced sales of Pura Vida branded products. Pura Vida merchandise includes hemp and CBD-related products and other products focusing on health and lifestyle which are available through established wholesale and distribution channels. In addition, a line of CBD pet supplements and other products are in development.

DVLP recently acquired “Where’s Weed” (Layer Six Media LLC DBA “Where’s Weed”) and its primary asset,?WheresWeed.com. Where’s Weed is an American cannabis technology company known for connecting medical and recreational cannabis users with trusted local marijuana businesses in their communities. As a rapidly growing community-based online resource for cannabis consumers with a host of user-friendly services, Where’s Weed offers a sophisticated mobile app with strong traction and powerful growth potential as the North American legal cannabis market continues to expand exponentially.

WheresWeed.com has a large and expanding reach with nearly 3 million pageviews per month. In addition, the WheresWeed mobile app, available in both iOS and Android, has been downloaded over 80,000 times, proving to be complementary to DVLP’s objective to capitalize on the massive growth curve in the marijuana space.

“The huge flood of new growers and producers is likely to create oversupply in the near term, narrowing margins for major producers,” says DVLP CEO Stavros Triant. “However, this should actually increase the net number of new consumers in the marketplace, further reinforcing the enormous growth potential for hub service providers in the space that are situated on high-traffic internet real estate, which is exactly how we view the Where’s Weed property.”

The company’s move into the lucrative C-store snack market was solidified with a material purchase order for CBD oils from a major distributor specializing in the snack foods and accessories to the convenience store and gas station market. The order represents significant progress as DVLP gears up its ready-made snack distribution strategy for its CBD products.

“We are extremely excited about the launch of our CBD product line with this distributor,” Triant states. “The C-Store strategy dovetails perfectly with our direct marketing strategy through our primary online retail channel, and we have indications from the distributor that, if this initial test order goes well, successive Purchase Orders could be significant and underpin strong sales growth in Q1 2019.”

Golden Developing Solutions, Inc. (DVLP), closed the day's trading session at $0.04, even for the day, on 4,076,119 volume with 288 trades. The average volume for the last 3 months is 552,924 and the stock's 52-week low/high is $0.0125/$0.14.

Recent News

• DVLP Enters Formal Negotiations to Acquire CBD Oil Company Featuring 300% YTD Sales Growth
• DVLP Announces Surging User Activity Results in Recently Acquired Where’s Weed App
• Golden Developing Solutions, Inc. (DVLP) is “One to Watch”

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

MARIJUANA COMPANY OF AMERICA INC. (OTC: MCOA), an innovative hemp and cannabis corporation, is pleased to announce that the Company filed an application with the OTC Markets on October 3, 2018, to uplist from the OTC Pink to the OTCQB listing tier on the OTC Markets. Also today, CannabisNewsWire put out an Audio Press Release titled “Public Acceptance Fuels Growth of CBD and Support Industries.” To hear the APR, visit: http://cnw.fm/e5T5K. To read the full editorial, visit: http://cnw.fm/D8gD3. Additionally, MCOA announced this morning that it has filed an application with the OTC Markets Group to uplist to the OTCQB Venture Market. To view the full press release, visit: http://nnw.fm/rC2qB.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.0251, off by 1.57%, on 14,526,878 volume with 537 trades. The average volume for the last 3 months is 7,645,653 and the stock's 52-week low/high is $0.022/$0.073.

Recent News

• Marijuana Company of America Applies for Uplisting to OTCQB and Finalizes S1 Registration Statement for Anticipated Equity Financing; Announces New Independent Director and Chief Financial Officer
• CannabisNewsAudio Announces Audio Press Release (APR) on Marijuana Company of America Inc. Sighting Progress and Opportunity in Harvesting Hemp
• NetworkNewsBreaks – Marijuana Company of America Inc. (MCOA) Files Application to Uplist to OTCQB Venture Market

Cannabis Strategic Ventures, Inc. (NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (NUGS).

Cannabis Strategic Ventures (OTC:NUGS) was highlighted today in a report examining how the global Cannabis market continues to receive favorable growth forecasts from experts as its multi-billion dollar projected revenues climb higher than most were thinking just a few short years ago.

Cannabis Strategic Ventures, Inc. (NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (NUGS), closed the day's trading session at $3.43, off by 4.72%, on 33,785 volume with 105 trades. The average volume for the last 3 months is 103,733 and the stock's 52-week low/high is $0.031/$7.13.

Recent News

• Favorable Outlook Continues to Boost Extraordinary Expectations for Cannabis Industry
• Cannabis Strategic Ventures Adds Board Member in Preparation of Uplisting of Common Stock to National Exchange
• Legal Cannabis Growing Market with Still a Mountain of Potential

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces that it has entered talks for a potential exclusive business/supply agreement with an organic CBD grower and processor.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

• Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
• Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
• KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $1.70, off by 1.90%, on 298,535 volume with 327 trades. The average volume for the last 3 months is 84,380 and the stock's 52-week low/high is $0.421/$2.45.

Recent News

• Earth Science Tech, Inc. (ETST) Enter into Talks with an Organic CBD Grower & Processor for an Exclusive Business/Supply Opportunity
• Earth Science Tech, Inc. (ETST) Promotes Women’s Health with Strategically Branded Self-sampling Kit
• Earth Science Tech, Inc. (ETST) Sees DEA Decision to Reschedule CBD Opening Doors for Development of Treatments for Multiple Illnesses

CytoDyn Inc. (CYDY)

The QualityStocks Daily Newsletter would like to spotlight CytoDyn Inc. (CYDY).

CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that Richard G. Pestell, M.D., Ph.D., President of the Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute Distinguished Professor, and Interim Chief Medical Officer of CytoDyn, will deliver the keynote plenary speech at the 11th Annual Conference on Stem Cell and Regenerative Medicine.

CytoDyn Inc. (CYDY) is a biotechnology company focused on the clinical development and potential commercialization of a new class of HIV/AIDS therapeutics or viral-entry inhibitors intended to protect healthy cells from viral infection. The company’s pipeline includes its lead product, PRO 140 for multiple indications among which are human immunodeficiency virus (HIV), graft-versus-host disease (GvHD), colon cancer, and multiple sclerosis (MS), each in various stages of development. CytoDyn first approval is focused on HIV indications for two different HIV populations.

PRO 140 is a humanized monoclonal antibody directed at CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 works by blocking the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5.

CytoDyn has completed one pivotal phase 3 clinical trials of PRO 140 use in combination with current drugs for population that has limited treatment options. PRO 140 is also currently in another phase 3 (investigative trial) for a second approval for another HIV population. HIV continues to be a major global public health issue. There is no cure for the disease that has claimed more than 35 million lives to date, according to the World Health Organization (“WHO”). In 2017, 940,000 people around the world died from HIV-related causes. There were approximately 36.9 million people living with HIV at the end of 2017 with 1.8 million people becoming newly infected during that same year. The WHO estimates there were 21.7 million people globally receiving antiretroviral therapy (“ART”) in 2017.

HIV targets the immune system and weakens the body’s defense systems against infections and some types of cancer. As the virus destroys and impairs the function of immune cells, infected individuals gradually become immunodeficient which results in increased susceptibility to a wide range of infections, cancers and other diseases that people with healthy immune systems can fight off. The most advanced stage of HIV infection is Acquired Immunodeficiency Syndrome (AIDS), which can take from 2 to 15 years to develop depending on the individual.

PRO 140 functions by blocking the HIV co-receptor CCR5, a molecular portal HIV uses to enter T-cells, thus preventing the HIV virus from entering the cell. CCR5 is a protein located on the surface of white blood cells that normally serves as a receptor for chemicals that attract immune cells to the site of inflammation. Clinical trials to date indicate PRO 140 does not interfere with these normal CCR5 functions. Results from phase 1 and phase 2 human clinical trials have shown PRO 140 significantly reduces viral burden in people infected with HIV. Importantly, in a recent phase 2b clinical trial, PRO 140 demonstrated it can allow a subset of R5 strain of HIV population to replace their current HIV regimen (Highly Active Antiretroviral Therapy or “HAART.”) by a simple sub-cutaneous self-injectable dose of PRO 140 which is administered once a week. Some of those patients have received PRO 140 as their only therapy for almost four years.

The PRO 140 antibody appears to be a powerful antiviral agent with hardly any side effects, toxicity. More than 500 patients have used PRO 140 in clinical trial and no resistance has ever been developed in any patients including patients in monotherapy of PRO 140 for almost four years.

PRO 140, which is taken as an easy-to-use, weekly, subcutaneous self-administered dose, has almost no side effects or toxicity with no report of any serious adverse event related to PRO 140 in more than 500 patients in eight different clinical trial.

As we indicated earlier patients given PRO 140 showed no drug resistance on monotherapy for some almost four years while 76% of HAART patients developed a resistance to some portion of the lifetime drug regimen. Patient compliance with HAART is also the main reason why only 35% of HIV patients in US reporting complete viral load (VL) suppression which is VL<50 cp/mL.

In addition to its research into the powerful potential of PRO 140 for use in HIV patients, CytoDyn is pursuing PRO 140 as a therapeutic anti-viral agent in other non-HIV indications that could benefit from PRO 140’s ability to block CCR5. These immunologic indications include new reactions to cancer, transplantation rejection, autoimmune diseases and chronic inflammation such as Multiple Sclerosis. The company sees the significant potential for multiple pipeline opportunities for PRO 140.

The U.S. Food and Drug Administration has designated PRO 140 as a “fast track” product for HIV and granted Orphan Drug Designation to it for the prevention of GvHD in transplant patients. CytoDyn has initiated its first clinical trial with PRO 140 in an immunological indication for GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation. The company is also investigating PRO 140 in animal models of cancer progression and autoimmunity with positive results and has published its animal study results in GvHD in peer-reviewed journal.

CytoDyn president and CEO Nader Z. Pourhassan, Ph.D. joined the company in 2008 and is credited for purchasing PRO 140 from Progenics in 2012 and has taken a new path to approval for the product. He is the co-inventor of monotherapy path for PRO 140. He has taken PRO 140 development from phase 2 to Completed successful phase 3 in about four years. He now has more than 10 years of drug development experience and has overseen the rapid clinical development of PRO 140 as a therapy for HIV into two phase 3 for two different indications. He also initiated PRO 140 first immunological indication in GvHD (currently in phase 2). He is also involved in preclinical and clinical development of PRO 140 in additional immunological indications.?Dr. Pourhassan, who has more than 20 years of business development experience, has led CytoDyn’s capital market activities since joining the company in 2008. He received his Bachelor of Science from Utah State University, Master of Science from Brigham Young University, and his Ph.D. in Mechanical Engineering from the University of Utah and is the author of three books.

CytoDyn Inc. (CYDY), closed the day's trading session at $0.5434, up 2.53%, on 39,622 volume with 26 trades. The average volume for the last 3 months is 361,583 and the stock's 52-week low/high is $0.40/$0.836.

Recent News

• CytoDyn Interim Chief Medical Officer Dr. Richard Pestell to Keynote 11th Annual Conference on Stem Cell and Regenerative Medicine
• CytoDyn Announces Strategy to Complete Development of Novel ProstaGene Gene-based Prostate Cancer Prognostic Test
• CytoDyn Inc. (CYDY) to Acquire Biotech Developing Therapies to Stop Cancer from Spreading

First Cobalt Corp. (TSX.V: FCC) (OTC: FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF).

Vertically integrated North American pure-play cobalt company First Cobalt (TSX.V: FCC) (OTCQX: FTSSF) (ASX: FCC) this morning released a corporate video highlighting the First Cobalt Refinery in Ontario, Canada. The video offers a look inside the company’s refinery, which is the only permitted cobalt refinery in North America capable of producing battery materials. The video, titled, “Get to Know the First Cobalt Refinery,” also includes comments from the company’s management team. The video is now available on the company's website at http://nnw.fm/KhcE6. To view the full press release, visit: http://nnw.fm/erg1X. Also today, NetworkNewsWire released a report on the company. To view the full publication, titled “Exponential Increase in EVs Drives New Cobalt Supply Chains,” visit: http://nnw.fm/VXo1I.

First Cobalt Corp. (TSX.V: FCC) (OTC: FTSSF), with headquarters in Canada, is the largest land owner in the Cobalt Camp in Ontario with control of over 10,000 hectares (nearly 25,000 acres) of prospective land and 50 historic cobalt/silver mines. The company’s assets include a mill and the only permitted cobalt extraction refinery in North America capable of producing battery material, providing an integrated solution for cobalt projects. First Cobalt began drilling in the historic Cobalt Camp in 2017 and seeks to build shareholder value through new discovery and growth opportunities.

First Cobalt’s 2018 $C7 million drilling program, which includes testing different styles of mineralized areas throughout the Cobalt Camp in more than 10 past-producing mines known to contain cobalt, is a significant expansion over its 2017 exploration activities. The company received positive test drill results from the Bellellen mine location, with early results confirming the presence of high-grade cobalt and nickel, prompting First Cobalt to increase its drilling program at that site. A prospecting sampling program of existing muckpiles around the camp’s historic mines, trenches, pits and surrounding bedrock could provide an early production scenario.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world’s current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

First Cobalt is embracing innovation in the mining sector, utilizing a digital compilation of 100-plus years of mining and geological data spanning the historically prolific Cobalt Mining Camp’s lifespan. First Cobalt’s management team is also assessing the ability of artificial intelligence to accelerate the discovery cycle. As a member of the Mineral Exploration Research Centre (MERC) and Metal Earth Project, First Cobalt conducts regional geophysical surveys for geological interpretation of structures controlling cobalt-silver mineralization.

The company’s clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance.

First Cobalt Corp. (FTSSF), closed the day's trading session at $0.2096, off by 4.94%, on 689,169 volume with 126 trades. The average volume for the last 3 months is 199,943 and the stock's 52-week low/high is $0.1983/$1.3041.

Recent News

• NetworkNewsBreaks – First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF) Posts Corporate Video Featuring its Refinery
• NetworkNewsWire Announces Publication on EV’s Need for Indispensable Li-ion Battery Drives New Demand for Cobalt
• First Cobalt Assessing Restart of Canadian Refinery

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

Cannabis-focused research and development company The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) this morning announced its entry into a strategic joint venture with LLACA Grupo Empresarial aimed at creating a 50/50-owned company to enter the medicinal cannabis market of Mexico. To view the full press release, visit: http://nnw.fm/8Gro9.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $4.15, off by 5.93%, on 1,278,926 volume with 2,940 trades. The average volume for the last 3 months is 947,740 and the stock's 52-week low/high is $2.784/$7.894.

Recent News

• NetworkNewsBreaks – The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Enters JV Targeting Mexican Medicinal Cannabis Market
• NetworkNewsBreaks – The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Issues Corporate Update
• The Green Organic Dutchman Closes Acquisition of Hempoland, Providing Immediate Accretive Revenue and International Sales

Phivida Holdings Inc. (CSE: VIDA) (OTC: PHVAF)

The QualityStocks Daily Newsletter would like to spotlight Phivida Holdings Inc. (PHVAF).

Phivida Holdings Inc. (CSE: VIDA) (OTC: PHVAF) highlighted today in a report on CBD beverages. The increasingly popular cannabis/hemp derivative cannabidiol (CBD) recently received its most important seal of approval, opening up the market to a potential wave of new CBD-infused products. Effective September 28, 2018, the US Drug Enforcement Administration (DEA), CBD has been downgraded from a Schedule I drug to Schedule V, allowing for FDA-approved drugs to contain the cannabinoid.

Headquartered in Vancouver, Canada, with operations offices in southern California, Phivida Holdings Inc. (CSE: VIDA) (OTC: PHVAF) is a premium food and beverage company that develops CBD-infused functional foods, beverages and supplements poised for global distribution. All products in the Phivida label are infused with organic, hemp-derived cannabinoids into a variety of premium foods, beverages and clinical products for everyday health. Phivida is guided by a team of Fortune 500-caliber executives focused on a new strategic portfolio of products and brands, comprehensive consumer research, new product and brand development, improved visual identity and packaging design, and a strong distribution strategy.

The company’s motto – “Celebrating Health and Wellness, in Harmony™” – underscores Phivida’s mission to lead the alternative health care sector as the benchmark standard in premium CBD-infused functional beverages and tinctures. To execute this goal, Phivida is taking advantage of positive legislative developments in the United States and has defined an elevated national route-to-market strategy across the U.S. where small regional distributors will be now be replaced with large national distributors.

Management

Phivida’s management team includes president and CEO Jim Bailey, former president of Red Bull Canada and global chief marketing officer for Merrell Outdoors; Chief Marketing Officer Michael Cornwell, former chief marketing officer for Samsung New Zealand and the former director of marketing for Red Bull Canada; and Doug Campbell, former director of sales for Red Bull North America, who as Phivida’s chief commercial officer is tasked with driving new sales revenue growth.

Publicly traded on the Canadian Securities Exchange (CSE.VIDA) and recently graduated to the OTCQX Best Market in the USA (OTCQX.PHVAF), the company’s strong balance sheet carries CAD$15.7 million with no debt or loans with less than 60 million shares outstanding and the company is now well-capitalized to fun major mainstream distribution with a solid structure poised for long-term growth.

The Science

Using encapsulation technology, Phivida uses full spectrum CBD-hemp oil (rich in naturally occurring phytocannabinoids) converted into a water-soluble delivery format, which enhances delivery and absorption of the cannabinoids into the human body – up to an estimated tenfold.

Encapsulated CBD is infused into functional beverages, food and supplements containing a proprietary blend of phytonutraceuticals studied to target a range of health and wellness conditions. Phivida tests every product for microbials, heavy metals, pesticides, residual solvents, terpenes, and potency to guarantee less than 0.3 percent THC (tetrahydrocannabinol, the chemical compound in cannabis responsible for a euphoric high) is present.

Regulations

Federally legal under the 2014 Farm Bill, CBD from Hemp Oil is a rapid growth market across the USA. When derived from marijuana, CBD remains a schedule one controlled substances, giving hemp derived CBD oil infused products a competitive advantage on regulations. On June 28, 2018, the U.S. Senate passed the Agriculture Improvement Act of 2018 (i.e. the “Farm Bill), lifting the USA Industrial Hemp laws to an agricultural commodity status and effectively removed hemp from the controlled substance list.

Earlier this year, another milestone court ruling also provided significant regulatory support for the US CBD-Hemp sector. In February 2018, the Supreme Court preceded over the HIA (Hemp Industry Association) vs. DEA (Drug Enforcement Agency) in a class-action suit concerning the issue of CBD extracted from hemp, and the legality of industrial hemp. In the final ruling the Supreme Court unequivocally determined that – when produced domestically under the Farm Bill – hemp (and its derivatives) are not a controlled substance.

The Supreme Court ruling also found the Farm Bill (as it relates to hemp) “pre-empts” the Controlled Substances Act. Congress has since exempted Farm Bill hemp from the Controlled Substances Act (CSA) giving the Farm Bill primary jurisdiction over the governance of the CBD-Hemp Oil industry in the USA.

The DEA further conceded it does not “seek to control cannabinoids,” and that only marijuana derived cannabinoids are governed under the Controlled Substances Act. In May of 2018, the DEA issued a formal directive to all federal agencies (e.g. US Customs and Border Patrol) stating that cannabinoids are not controlled substances unless derived from marijuana, and that the “mere presence of cannabinoids” in any product or derivative does not render it a controlled substance. The Supreme Court ruling also resulted in the mediation of a settlement in what is now the third successful HIA vs. DEA suit in over a decade.

In Canada, the Senate approval of Bill C-45 legalized the production, distribution and use of recreation cannabis – with edibles to be added in 2019. The bill will officially become law as of October 17, 2018, creating a legal framework for the production, distribution, sale and possession of cannabis across Canada including cannabinoid-infused beverages.

3 Wholly Owned Subsidiaries

• Phivida Organics Inc. offers professional-grade, wholesale, whole plant hemp oil extracts made from 100-percent certified organic hemp stalk. Phivida’s hemp oil extracts are CO2-extracted under quality assurance/clinical standards and are third-party lab tested to assure only pharmaceutical grade, cGMP certified, full-spectrum products are produced and available for sale. Phivida Organics produces hemp oil extracts that deliver nano-encapsulated cannabinoids in water soluble formulations designed to be absorbed up to 10 times faster than other oils, providing up to 400 percent bioavailability. Phivida Hemp Oil Vida+ extract products are available now online at www.Phivida.com.
• Phivida Nutrition blends the best of nature into CBD-infused lifestyle branded beverages including a variety of CBD infused iced teas and CBD infused flavored waters.
• Phivida Enhanced – Under the VIDA brand, CBD-infused tinctures, capsules and other supplement products are distributed to alternative health care clinics across the USA.

WeedMD-Phivida

Phivida has signed a binding letter of intent to joint venture WeedMD Inc. (TSX-V: WMD) (OTC:WDDMF) (FSE:4WE), a Health Canada federally licensed producer and distributor of medical cannabis, to form a joint venture focused on cannabis-infused beverages. The new joint-venture company, Cannabis Beverages Inc. (“CanBev”), plans to develop a production facility at WeedMD’s state-of-the-art greenhouse facility in Strathroy, Ontario, Canada. CanBev is on track to build and operate the first cannabis-infused beverage production facilities in Canada. The joint venture will focus on manufacturing, marketing and distribution of cannabinoid-infused beverages for the legalized medical and adult-use cannabis markets.

Management from both WeedMD and Phivida are collaborating on design and engineering strategies and site evaluations on a 610,000-square-foot, state-of-the art facility in Strathroy for the development of CanBev. As an emerging certified food grade production plant, the Strathroy facility is an ideal location and comes is equipped with extensive production infrastructure, including 50,000 sq. ft. of food production and packaging area, cold storage, loading docks, and adequate space to expand for future growth.

Strategic Agreements

Phivida Organics has also entered into an agreement to carry out a pharmacokinetic (PK) study on its hemp-derived, nanoencapsulated CBD with Artelo Biosciences Inc. at the University of Nottingham, School of Medicine at the Royal Derby Hospital, England. The study will test encapsulated-CBD on healthy volunteers and measure how fast and how much CBD enters the blood stream after oral consumption with each of the different formulations developed by Phivida Organics.

Phivida has also activated distribution agreements with Asayake Inc. to become one of the first federally approved CBD-infused food and supplement brands in Japan. With first mover status achieved, Phivida now markets to an underserved, yet highly informed population of 127 million patients and practitioners. The supplement market in Japan is estimated at US$10 billion with the overall functional foods market at US$21 billion. The Asia-Pacific region is the fastest growing market for natural plant-based supplements. Phivida now plans to prepare a formal application to Japan’s Consumer Affairs Agency to register the company’s CBD-infused functional food and beverage products for approval under the country’s Food with Functional Claims regime. The functional beverage market in Japan is estimated at US$10.35 billion with a CAGR of 2.5 percent (2015-2025).

Further Information

www.Phivida.com
+1 (844) 744-6646 (ext. #2)
IR@Phivida.com

Phivida Holdings Inc. (PHVAF), closed the day's trading session at $0.6571, off by 5.45%, on 118,037 volume with 68 trades. The average volume for the last 3 months is 100,239 and the stock's 52-week low/high is $0.05/$1.80.

Recent News

• Market Potential for Cannabis-Infused Beverages Unleashed as DEA Removes CBD as Schedule 1 Drug
• Phivida comments on the removal of CBD from U.S. DEA Schedule 1 and announces share issuance
• NetworkNewsBreaks – Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) Issues Response to DEA Rescheduling of CBD

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF)

The QualityStocks Daily Newsletter would like to spotlight FinCanna Capital Corp. (FNNZF).

FinCanna Capital (CSE: CALI) (OTCQB: FNNZF), a royalty company for the U.S. licensed medical cannabis industry, this morning announced that its investee company ezGreen Compliance has expanded its proprietary Business Intelligence Dashboard (“BID”) by adding a new comprehensive taxation feature to automate crucial revenue reporting functionality. To view the full press release, visit: http://nnw.fm/3HhJd.

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) is a royalty company aiming to be the capital partner of choice for high-growth, best-in-class businesses operating in the licensed U.S. medical cannabis industry. Primarily focused on the burgeoning California cannabis market, FinCanna leverages extensive investment expertise and industry experience to benefit its shareholders and portfolio companies.

Medical Cannabis Market

According to Ameri Research, the global market for licensed medical cannabis is growing at a compound annual growth rate (CAGR) of more than 21%, on track to exceed $63.5 billion by 2024. Within this market, FinCanna has identified considerable opportunity in California, the fifth largest economy in the world and the largest medical cannabis market in North America. Arcview Group forecasts California’s legal cannabis industry will grow at 21.1% CAGR to $6.5 billion in 2020, generating more than $1 billion in tax revenue.

Royalty Model & Portfolio

FinCanna’s “whole capital” solution for businesses in the licensed medical cannabis sector includes the provision of capital investment for a percentage of their future revenues. The FinCanna Capital Solution utilizes a royalty arrangement to deliver capital, in order to facilitate the growth or other specific objectives of its investees, and ensure the business opportunity is optimized. This model provides an alternative or complement to debt and equity financing, allowing investees to maintain financial flexibility and control of their business rather than entering into arrangements that may include restrictive debt structures or giving up an ownership stake.

FinCanna’s portfolio includes Cultivation Technologies, Inc. (“CTI”), a team of experts from Fortune 150 agriculture, medical cannabis, law, engineering and technology companies. FinCanna is providing funding to CTI for its planned, fully entitled, large-scale indoor medical cannabis facility to be developed in Coachella, California.

CTI has established an interim medical cannabis extraction facility (the “Interim Facility”) that will produce licensed medical cannabis products until the Coachella Project is complete. CTI is currently expanding its product line, Coachella Premium, to include vaporizer cartridges. Initial market feedback gathered during the product development phase indicates that Coachella Premium’s vaporizer cartridges offer a unique proposition within the vaporizer market, one of the fastest growing verticals in the cannabis market.

The Interim Facility can process up to 6,000 pounds of biomass per month, the equivalent of approximately 3.7 million grams of raw oil per year, with room for expansion. It is expected that the completed Coachella Project will be able to process 30,000 to 50,000 pounds of biomass per month, or the equivalent of 18 million grams to 30 million grams of raw oil per year.

Additionally FinCanna has entered into a royalty agreement with Green Compliance, a provider of point-of-sale software solution (“ezGreen”) for licensed medical cannabis dispensaries and cultivators. Green Compliance helps its customers comply with both the Health Insurance Portability and Accountability Act (“HIPAA”) and State Laws by ensuring patients’ confidential data is being handled properly, helping to protect from possible security breaches and financial and criminal liability resulting from potential violations.

FinCanna has also signed binding term sheet with Oakland, California-based Gram Co Holdings, subject to due diligence by FinCanna. Gram Co is a cannabinoid research and refinement facility focused providing B2B and B2C products and services to licensed medical dispensaries, infused product manufacturers, and numerous others in the cannabis supply chain. The company is also retrofitting a large, state-of-the-art medical cannabis extraction laboratory, which is expected to be operating in 2018.

The foregoing contains forward-looking statements regarding Cultivation Technologies Inc. (“CTI”) which are subject to risks, uncertainties and contingencies which include, but are not limited to the statements relating the future construction and completion of the CTI medical cannabis facility in Coachella, California, and the projected biomass processing and raw oil production at the facility. Such forward looking statements are based on assumptions regarding the construction, completion and operations of CTI’s proposed facility, including that CTI will obtain the financing required to build and equip its proposed facility, that CTI will obtain the additional financing required operate the facility, that construction facility is completed on time and budget, that CTI obtains state licenses to operate on a permanent basis, and that the equipment used in the cultivation of medical cannabis performs at scale in a similar way it performs at CTI’s pilot tests.

FinCanna Capital Corp. (FNNZF), closed the day's trading session at $0.1904, off by 8.90%, on 11,973 volume with 11 trades. The average volume for the last 3 months is 41,759 and the stock's 52-week low/high is $0.10/$0.8736.

Recent News

• NetworkNewsBreaks – FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) Investee Adds Taxation Reporting Technology to its Proprietary Compliance Platform
• FinCanna to Receive ~$3.9M USD Cash and Retain 3.44% Royalty in Perpetuity from CTI Royalty Restructuring Agreement
• 420 with CNW – Connecticut Federal Court Rules in Favor of Employees Taking Medical Marijuana

Lithium Chile Inc. (TSX.V: LITH) (OTC: LTMCF)

The QualityStocks Daily Newsletter would like to spotlight Lithium Chile Inc. (LTMCF).

Lithium Chile Inc. (TSX.V: LITH) (OTC: LTMCF) is pleased to announce it has encountered lithium bearing brines in three additional drill holes at its wholly owned Ollague Project, Chile. Results for OLL-01-18, OLL-02-18, OLL-03-18 and OLL-04-18 are outlined in the table below. Drilling continues to confirm the reliability of TEM geophysical profiles in identifying the brine carrying highly conductive zones. In addition, the drilling suggests that lithium grades increase with depth. Also today, NetworkNewsWire released a report on the company. After securing one of the largest lithium land holdings in one of the largest lithium-producing nations on Earth, mineral explorer Lithium Chile Inc. (TSX.V: LITH) (OTCQB: LTMCF) is expecting good news resulting from its drilling program near Chile’s northeastern border with Bolivia.

Lithium Chile Inc. (TSX.V: LITH) (OTC: LTMCF), headquartered in Canada, is advancing one of the largest lithium-rich exploration portfolios in Chile consisting of more than 148,000 hectares covering sections of 13 salars or mineral salt flats and one laguna complex. The company’s wholly owned premier properties include 66 square kilometers on the Salar de Atacama, Chile’s largest mineral salt flat which hosts the world’s highest concentration of lithium brine production and is currently the source of about 35 percent of the world’s lithium production. Lithium Chile also owns a significant copper/gold/silver property portfolio consisting of 28,184 hectares over six different properties.

Lithium Chile’s portfolio in the heart of Chile’s lithium-rich salars includes Salar de Coipasa, Salar de Helados, Salar de Atacama, Salar de Turi Salar de Ollague and Salar de Talar. Surface and near surface salt and brine sampling programs on all properties has been completed. To date, samples of high-grade, near-surface lithium brines at each of these projects are showing excellent chemistry of lithium to potassium and lithium to magnesium ratios. Good chemistry is important as it reduces your overall cost of production. Recent geophysical surveys including T.E.M have been completed on 5 of 6 priority targets and data collected to date has been extremely encouraging.

Lithium Chile has identified multiple high-priority brine target areas at its Atacama and Ollague lithium project areas. These areas display the same geophysical characteristics as the lithium-rich aquifers at Salar de Atacama, home to the world’s largest and highest-grade lithium brine producers. Spanning an area of 1,200 square miles, Salar de Atacama is the world’s third largest salt flat behind Salinas Grandes in Argentina and El Salar de Uyuni in neighboring Bolivia. Exploration drilling and resource definition drilling for these target areas are planned for 2018.

“We are delighted with the discovery of such impressive drill target areas at Atacama and Ollague. The results also follow the recent discovery of a 60km2 target area at another of our top Chilean projects – Helados – where we hope to drill in the second quarter of 2018,” stated President and CEO Steve Cochrane. “We have an aggressive multi-project drill program planned for this year, which includes all three of these exciting projects and we look forward to sharing drill results as they come through.”

Global demand for lithium-ion batteries is expected to surpass US$53 billion by 2024 as governments around the world aggressively seek to ban gas-powered vehicles and major automakers invest billions in new technology and electric vehicles powered by lithium-ion batteries. Chile’s mining-friendly jurisdiction offers Lithium Chile a clear, streamlined permitting process that significantly lowers the cost of lithium production to around $1,800/ton as compared to Australia’s $5,000/ton.

Lithium Chile is led by an experienced team with strong Chilean connections. Cochrane’s 36 years of investment industry experience have primarily been focused on the mining sector. During this time, he raised more than US$500 million for a variety of small cap public companies in various businesses and industry sectors including mining.

Terry Walker, P.Geol., vice president of exploration and chief geologist, is a highly experienced geologist. He has spent over 25 years in Chile’s mining industry and is well connected throughout the sector. Walker is co-founder of GeoServicios Piedra Dorada, an exploration and development services company focused on Latin America. He is a Qualified Person for the North American and Australian stock exchanges.

Lithium Chile is well funded and driven by a top-tier team with more than 100 years of combined experience in financing, mining exploration and development in the natural resources sector.

Lithium Chile Inc. (LTMCF), closed the day's trading session at $0.513741, off by 10.23%, on 161,709 with 113 trades. The average volume for the last 3 months is 46,697 and the stock's 52-week low/high is $0.4797/$0.97.

Recent News

• Lithium Chile Continues to Intercept Lithium Brines on its Olllague Drill Program
• Lithium Chile Inc. (TSX.V: LITH) (OTCQB: LTMCF) Well Placed for Metal Discoveries in South America’s Lithium Triangle
• Lithium Chile Inc. (TSX.V: LITH) (OTCQB: LTMCF) Drills Deeper Under Encouraging Conditions as Global Lithium Demands Rise

RYU Apparel, Inc. (TSX.V: RYU) (OTC: RYPPF) (FRA: RYA)

The QualityStocks Daily Newsletter would like to spotlight RYU Apparel, Inc. (RYPPF).

RYU Apparel Inc. (TSX VENTURE: RYU.V, OTCQB: RYPPF), creators of urban athletic apparel, is pleased to share multiple high-profile exposure of the brand's new innovative products, in several articles published by online global publication PopSugar. Also today, NetworkNewsWire released a report on the company. To view the full publication, titled “Athleisure Wear Is Crushing It on the Street,” visit: http://nnw.fm/kGIl7.

Engineered for the fitness, performance and lifestyle of the athletically-minded, RYU Apparel, Inc. (DBA RYU \ Respect Your Universe) (TSX-V: RYU) (OTC: RYPPF) (FRA: RYA) develops, markets and distributes apparel, bags and accessories for active people living their lives with integrity. Headquartered in Vancouver, Canada, with with four stores located in Greater Vancouver Area, British Columbia and one in Toronto, RYU opened its first U.S.-based store at the iconic Abbot Kinney Boulevard in Venice California, on August 2, 2018. Additional retail locations are slated to open soon in Etokicoke, Ontario, Canada; Brooklyn, New York; and Newport Beach, California, with plans to establish nearly two dozen more store locations by the end of 2022.

Respect Your Universe’s award-winning brand celebrates, encourages and respects an individual’s choices and journey in life, promoting a fitness lifestyle culture. Innovatively designed without compromise and tailored for fit, comfort and durability, RYU exists to facilitate human performance. RYU’s urban athletic apparel and accessories product line has been featured by some of the most influential fitness and outdoor lifestyle publications and social media connectors.

The company recently was honored in Madrid, Spain, as a 2018 Finalist in the World Retail Awards in the categories of “Retail Start Up of the Year” and “Social Media Campaign of the Year,” (#RYUOneMoreRep). RYU is one of only two Canadian companies that qualified as finalists among many global retailers across all categories of the World Retail Awards annual event. The World Retail Awards have been recognizing the very best retailers and retail initiatives across a range of categories since 2007.

Marcello Leone, CEO of RYU, said the company’s inclusion in the prestigious lineup of finalists was gratifying, stating, “Being chosen by the World Retail Awards is a fantastic accolade. We are proud to be among a group of global peers that are considered to become the next generation of iconic brands. #RYUOneMoreRep Media Campaign is also another confirmation of the social aspect that permeates our brand and the impact we are having in our community.”

In addition to its retail locations, RYU generates sales through its e-commerce platform and has developed strategic relationships with companies such as Global-E, Netamorphosis, Fancy and the NHL Vancouver Canucks to expand its reach. RYU is also building connections with influential leaders and social media influencers who represent the company’s values of aliveness, bold expression, curiosity, discipline and respect. Under RYU’s Connector Program, each leader actively engages in community charities, volunteer efforts and participates in charity programs. Among the famous personalities and community leaders connecting with the RYU brand are:

• Alexandra Ianculescu, a Canadian National Team Olympic Speed Skater
• Ben Carr, professional trainer
• Tori Katongo, personal trainer, singer, actor, dancer
• Simon “Thor” Damborg, head coach at Raincity Athletics
• Cassie Hawrysh, a Canadian National Team Skeleton Racer
• Dai Manuel, lifestyle mentor and author of “The WholeLife Manifesto”

Company CEO Leon is the founder of Naturo Group Investment Inc., a company that sells nutritional beverages, and also is the former VP of operations and president of LEONE, an independent high fashion specialty store in Vancouver, Canada. Chief Financial Officer Pedro Villa is a certified CPA who has held several senior positions in various North American companies. Brett Pawson, senior VP of retail and operations, has more than 15 years of experience in sales and operations in the wellness, consumer goods and retail sectors.

RYU’s strategic focus is on becoming a global leader as a fitness and training apparel and accessories brand for athletes in multiple disciplines. RYU’s goal is to facilitate human performance by honoring and celebrating the extraordinary oneness of humanity by respecting each other’s differences – Respect Your Universe.

RYU Apparel, Inc. (RYPPF), closed the day's trading session at $0.1515, off by 9.16%, on 59,737 volume with 20 trades. The average volume for the last 3 months is 78,890 and the stock's 52-week low/high is $0.05/$0.255.

Recent News

• RYU Products Featured in PopSugar
• NetworkNewsWire Announces Publication on Athleisure Wear Creating Lucrative New Revenue Streams for Innovative Businesses
• RYU Product Featured in SHAPE

Koios Beverage Corp. (CSE: KBEV) (OTC: KBEVF)

The QualityStocks Daily Newsletter would like to spotlight Koios Beverage Corp. (KBEVF).

Koios Beverage Corp.(CSE: KBEV; OTC: KBEVF:US) (the "Company" or "Koios"), is pleased to introduce single-serving samples of its brain-healthy proprietary nootropics powder, starting with its most popular flavour, blueberry lemonade. Also today, the company was highlighted by CannabisNewsWire analyzing how cannabis industry players in the U.S. are concerned that the stubborn insistence on prohibition by the federal government will give Canadian producers a chance to dominate the marijuana industry.

Koios Beverage Corp. (CSE: KBEV) (OTC: KBEVF) develops and distributes nature-based products that boost brain function, enhance health, and improve productivity. Its core vision is to help a billion people worldwide live more productively through the development of nootropics, which are supplements that improve cognitive abilities.

The company’s flagship product, Koios, is a GMP-certified dietary supplement. Made from natural ingredients and backed by science, Koios is designed to improve focus, memory, mental drive, clarity and energy. The company produces Koios in the following formulations:

• Powder supplements containing nootropics as well as caffeine and lion’s mane and chaga mushrooms;
• Vegan-friendly capsules;
• Canned beverages containing nootropics along with MCT oil to burn fat and increase metabolism.

Not to be mistaken with prescription-only drugs which are at times used for similar effects, nootropics are over-the-counter dietary supplements; some of which, like Koios, contain ingredients that are currently used in the treatment of patients with Alzheimer’s disease. The global field of nootropics is growing rapidly and expected to reach USD $6,059.4 Mn by 2024 with a CAGR of 17.9 percent from 2016 to 2024.

According to media reports, there is believed to be significant and growing use of nootropics among high-achieving students and professionals. The UK’s leading Guardian newspaper found that nootropics are commonly used in Silicon Valley by computer industry professionals who want to “hack” their minds and maximize their productivity without any possible negative effects on the brain.

Koios was born out of the personal struggles of its founder and CEO, Chris Miller, who has ADHD. Miller found that the symptoms of his condition held him back when navigating the competitive modern workplace. Unhappy with the effects of the Adderall he was prescribed, Chris began a search for a natural remedy that would improve his attention and mental capacity.

Speaking of his struggles at this time, Miller says, “Coffee and energy drinks were no longer helping me. Eventually, I was drinking so much caffeine that I was beginning to notice negative and troubling health effects.” He adds, “I believed there had to be a better way. Better technology that the earth was providing that I could implement and not only boost my daily performance but take care of my brain and body long-term.” After years of experiments and with the help of leading scientists, he developed Koios, named after the Greek Titan who represented rational intelligence.

Koios contains the following ingredients, among others:

• Vitamin B12: Crucial for the function of the nervous system and the synthesis of DNA, B12 also helps in the creation of red blood cells.
• Vitamin B6: This vitamin is crucial for brain development among children and brain function in adults. B6 is also important in the production of key hormones: serotonin, which regulates mood, norepinephrine, which helps us handle stress, and dopamine.
• Huperzine A: Developed from the Chinese club moss plant, huperzine A is used on Alzheimer’s patients to boost their memories. It is also used to raise energy levels and alertness and is the subject of medical trials to test its efficacy when combined with other drugs.
• Bacopa: Also known as brahmi, bacopa is an Indian herb used in Ayurvedic medicine to improve concentration and memory. Modern science has recognized its effectiveness, and it is used to treat symptoms caused by Alzheimer’s disease, ADHD and anxiety.
• Ciwujia: Sports scientists have been interested in this herb since they heard of how mountain climbers in Tibet use it to boost their performance at high altitudes. Peer-reviewed research has shown that Ciwujia has clear positive effects on endurance.

A full breakdown of Koios’ active ingredients is available on the company website.

Additionally, safety is paramount for Koios, with all its products developed in a high-grade nutraceutical laboratory which is GMP-certified and in compliance with FDA guidelines. Koios only uses high-quality ingredients sourced from the best possible locations in order to deliver a product that is not only safe but also “one of the world’s greatest nootropic blends.”

The company’s products can be found online and in stores, both across the United States and internationally, via a continuously growing distribution network.

Koios CEO Chris Miller is supported by a team with strong credentials in medical supplement start-ups, corporate finance and sales, which includes CFO/Director Anthony Jackson, Director Scott Walters, Director Konstantine Lichtenwald and Vice President of Sales Gina Burrus.

With people seeking a mental edge and cognitive boost, Koios believes that there is an opening in the market for its nature-based, over-the-counter nootropics, especially when current prescription medicines have worrying side effects..

Koios Beverage Corp. (KBEVF), closed the day's trading session at $0.41, off by 14.58%, on 434,097 volume with 157 trades. The average volume for the last 3 months is 446,376 and the stock's 52-week low/high is $0.001/$0.814.

Recent News

• Koios Beverage Corp Begins Production of Single-Serving Stick Packages
• 420 with CNW – American Cannabis Producers Fear Canadian Industry Dominance
• Clinical Trial Shows Positive Brain Activity Linked to Koios Beverages